Dr Reddys Laboratories Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
6709.60 +91.70 (1.39%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6630.8
Today’s High
6744
52 Week Low
5212.1
52 Week High
7101
6710.90 +99.25 (1.50%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6629.05
Today’s High
6745.95
52 Week Low
5205.55
52 Week High
7107.45
Key Metrics
- Market Cap (In Cr) 110145.2
- Beta 0.26
- Div. Yield (%) 0.6
- P/B 3.9
- TTM P/E 19.15
- Peg Ratio 6.63
- Sector P/E 36.27
- D/E -
- Open Price 6664.95
- Prev Close 6617.9
Dr Reddys Laboratories Analysis
Price Analysis
-
1 Week-0.67%
-
3 Months-0.52%
-
6 Month9.28%
-
YTD14.04%
-
1 Year20.36%
Risk Meter
- 18% Low risk
- 18% Moderate risk
- 18% Balanced Risk
- 18% High risk
- 18% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 6
- 6
- 6
- 6
- Buy
- 4
- 4
- 4
- 5
- Hold
- 9
- 9
- 9
- 10
- Sell
- 11
- 11
- 10
- 7
- Strong Sell
- 4
- 4
- 4
- 4
- Total
- 34
- 34
- 33
- 32
Dr Reddys Laboratories News
Dr Reddys Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 28011.1
- Selling/ General/ Admin Expenses Total
- 11869
- Depreciation/ Amortization
- 1470
- Total Operating Expense
- 21395.6
- Operating Income
- 6615.5
- Net Income Before Taxes
- 7201
- Net Income
- 5577.9
- Diluted Normalized EPS
- 327.52
- Period
- 2024
- Total Assets
- 38863.8
- Total Liabilities
- 10609
- Total Equity
- 28254.8
- Tangible Book Valueper Share Common Eq
- 1441.77
- Period
- 2024
- Cashfrom Operating Activities
- 4543.3
- Cashfrom Investing Activities
- -4028.3
- Cashfrom Financing Activities
- -376.3
- Net Changein Cash
- 132.8
- Period
- 2023
- Total Revenue
- 24669.7
- Selling/ General/ Admin Expenses Total
- 8204.8
- Depreciation/ Amortization
- 1250.2
- Total Operating Expense
- 19449.8
- Operating Income
- 5219.9
- Net Income Before Taxes
- 6048.5
- Net Income
- 4507.3
- Diluted Normalized EPS
- 279.44
- Period
- 2023
- Total Assets
- 32285.1
- Total Liabilities
- 8999
- Total Equity
- 23286.1
- Tangible Book Valueper Share Common Eq
- 1183.6
- Period
- 2023
- Cashfrom Operating Activities
- 5887.5
- Cashfrom Investing Activities
- -4137.3
- Cashfrom Financing Activities
- -2686.1
- Net Changein Cash
- -907.3
- Period
- 2022
- Total Revenue
- 21545.2
- Selling/ General/ Admin Expenses Total
- 7339.9
- Depreciation/ Amortization
- 1165.2
- Total Operating Expense
- 18942.7
- Operating Income
- 2602.5
- Net Income Before Taxes
- 3061.4
- Net Income
- 2182.5
- Diluted Normalized EPS
- 165.95
- Period
- 2022
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021
- Total Revenue
- 19047.5
- Selling/ General/ Admin Expenses Total
- 6385.1
- Depreciation/ Amortization
- 1228.8
- Total Operating Expense
- 16402.2
- Operating Income
- 2645.3
- Net Income Before Taxes
- 2883.5
- Net Income
- 1951.6
- Diluted Normalized EPS
- 142.73
- Period
- 2021
- Total Assets
- 26616.8
- Total Liabilities
- 8975.1
- Total Equity
- 17641.7
- Tangible Book Valueper Share Common Eq
- 818.04
- Period
- 2021
- Cashfrom Operating Activities
- 3570.3
- Cashfrom Investing Activities
- -2266
- Cashfrom Financing Activities
- -29.8
- Net Changein Cash
- 1285.8
- Period
- 2020
- Total Revenue
- 17517
- Selling/ General/ Admin Expenses Total
- 5881
- Depreciation/ Amortization
- 1163.1
- Total Operating Expense
- 16203
- Operating Income
- 1314
- Net Income Before Taxes
- 1885.7
- Net Income
- 2026
- Diluted Normalized EPS
- 187.62
- Period
- 2020
- Total Assets
- 23225.3
- Total Liabilities
- 7626.5
- Total Equity
- 15598.8
- Tangible Book Valueper Share Common Eq
- 749.67
- Period
- 2020
- Cashfrom Operating Activities
- 2984.1
- Cashfrom Investing Activities
- -492.3
- Cashfrom Financing Activities
- -2515.9
- Net Changein Cash
- -26.6
- Period
- 2019
- Total Revenue
- 15448.2
- Selling/ General/ Admin Expenses Total
- 5839.9
- Depreciation/ Amortization
- 1134.8
- Total Operating Expense
- 13404.8
- Operating Income
- 2043.4
- Net Income Before Taxes
- 2292
- Net Income
- 1950
- Diluted Normalized EPS
- 111.64
- Period
- 2019
- Total Assets
- 22465.6
- Total Liabilities
- 8442
- Total Equity
- 14023.6
- Tangible Book Valueper Share Common Eq
- 559.81
- Period
- 2019
- Cashfrom Operating Activities
- 2870.4
- Cashfrom Investing Activities
- -772.7
- Cashfrom Financing Activities
- -2132.6
- Net Changein Cash
- -31.4
- Period
- 2024-06-30
- Total Revenue
- 7696.1
- Selling/ General/ Admin Expenses Total
- 3384
- Depreciation/ Amortization
- 380.6
- Total Operating Expense
- 5946.8
- Operating Income
- 1749.3
- Net Income Before Taxes
- 1882.6
- Net Income
- 1392.4
- Diluted Normalized EPS
- 83.5
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 7113.8
- Selling/ General/ Admin Expenses Total
- 3207.8
- Depreciation/ Amortization
- 367.7
- Total Operating Expense
- 5650.3
- Operating Income
- 1463.5
- Net Income Before Taxes
- 1605.2
- Net Income
- 1309.8
- Diluted Normalized EPS
- 77.68
- Period
- 2024-03-31
- Total Assets
- 38863.8
- Total Liabilities
- 10609
- Total Equity
- 28254.8
- Tangible Book Valueper Share Common Eq
- 1441.77
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4543.3
- Cashfrom Investing Activities
- -4028.3
- Cashfrom Financing Activities
- -376.3
- Net Changein Cash
- 132.8
- Period
- 2023-12-31
- Total Revenue
- 7236.8
- Selling/ General/ Admin Expenses Total
- 3026.7
- Depreciation/ Amortization
- 373.5
- Total Operating Expense
- 5587.2
- Operating Income
- 1649.6
- Net Income Before Taxes
- 1829.1
- Net Income
- 1380.9
- Diluted Normalized EPS
- 83.31
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 6902.6
- Selling/ General/ Admin Expenses Total
- 2885.8
- Depreciation/ Amortization
- 375.5
- Total Operating Expense
- 5171.4
- Operating Income
- 1731.2
- Net Income Before Taxes
- 1916.7
- Net Income
- 1482.2
- Diluted Normalized EPS
- 84.6
- Period
- 2023-09-30
- Total Assets
- 34809.4
- Total Liabilities
- 9312.6
- Total Equity
- 25496.8
- Tangible Book Valueper Share Common Eq
- 1277.13
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 2917.6
- Cashfrom Investing Activities
- -1275.3
- Cashfrom Financing Activities
- -851.2
- Net Changein Cash
- 775.6
- Period
- 2023-06-30
- Total Revenue
- 6757.9
- Selling/ General/ Admin Expenses Total
- 2757.1
- Depreciation/ Amortization
- 353.3
- Total Operating Expense
- 4995.1
- Operating Income
- 1762.8
- Net Income Before Taxes
- 1850
- Net Income
- 1405
- Diluted Normalized EPS
- 81.95
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 6315.2
- Selling/ General/ Admin Expenses Total
- 2829.2
- Depreciation/ Amortization
- 315.5
- Total Operating Expense
- 5096.7
- Operating Income
- 1218.5
- Net Income Before Taxes
- 1329.2
- Net Income
- 960.2
- Diluted Normalized EPS
- 60.01
- Period
- 2023-03-31
- Total Assets
- 32285.1
- Total Liabilities
- 8999
- Total Equity
- 23286.1
- Tangible Book Valueper Share Common Eq
- 1183.6
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5887.5
- Cashfrom Investing Activities
- -4137.3
- Cashfrom Financing Activities
- -2686.1
- Net Changein Cash
- -907.3
- Period
- 2022-12-31
- Total Revenue
- 6789.8
- Selling/ General/ Admin Expenses Total
- 2836.5
- Depreciation/ Amortization
- 323.7
- Total Operating Expense
- 5175
- Operating Income
- 1614.8
- Net Income Before Taxes
- 1637.7
- Net Income
- 1243.9
- Diluted Normalized EPS
- 75.37
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Dr Reddys Laboratories Technical
Moving Average
SMA
- 5 Day6635.39
- 10 Day6665.77
- 20 Day6660.42
- 50 Day6778.57
- 100 Day6518.76
- 300 Day6289.84
Dr Reddys Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Cipla
- 1563.8
- -7.65
- -0.49
- 1702
- 1132
- 126260.43
- Torrent Pharmaceuticals
- 3505.7
- 8.3
- 0.24
- 3589.95
- 1822.8
- 118653.92
- Dr Reddys Laboratories
- 6709.6
- 91.7
- 1.39
- 7101
- 5212.1
- 111733.95
- Zydus Lifesciences
- 1019.65
- -38.55
- -3.64
- 1323.9
- 567.85
- 102576.79
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Cipla
- 29.73
- 4.83
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 73.67
- 17.23
- 20.64
- 13.18
- Dr Reddys Laboratories
- 20.16
- 3.93
- 16.73
- 14.63
- Zydus Lifesciences
- 28.02
- 5.39
- 15.65
- 14.33
- Lupin
- 49.46
- 7.16
- 2.51
- 2.04
Dr Reddys Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 05-Nov-24
- Quarterly Results
- 27-Jul-24
- Quarterly Results & Stock Split
- 07-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 10-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results
- 28-Oct-22
- Quarterly Results
- 28-Jul-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Jul-24
- 07-May-24
- AGM
- 15-Feb-24
- 15-Jan-24
- POM
- 16-Nov-23
- 16-Oct-23
- POM
- 27-Jul-23
- 10-May-23
- AGM
- 29-Jul-22
- 20-May-22
- AGM
- 29-Mar-22
- 25-Feb-22
- POM
- 28-Jul-21
- 20-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 07-May-24
- -
- 16-Jul-24
- 40
- 10-May-23
- -
- 11-Jul-23
- 40
- 19-May-22
- -
- 11-Jul-22
- 30
- 14-May-21
- -
- 09-Jul-21
- 25
- Ex-Splits
- Old FV
- New FV
- Description
- 28-Oct-24
- 5
- 1
- Stock Split from Rs. 5/- to Re. 1/-